Psychedelic-Assisted Therapies turns a fast-moving evidence base into clinic routines that protect safety, dignity, and outcomes. We start with plain-language formulation: who may benefit (e.g., chronic, impairing depression and PTSD after disciplined first- and second-line care), who should wait (active psychosis/mania, unstable cardiovascular disease), and what “assisted” really means—structured preparation, carefully staffed dosing days, and integration sessions that translate insights into daily behaviors. Consent covers realistic effect sizes, variability in response, and the workload of therapy around dosing; expectations are set for sleep protection, substance use guidance, and support plans between sessions. Programs emphasize low-tech anchors that potentiate learning (fixed wake time, morning light, brief activation) and trauma-informed delivery that reduces shame and coercion risk. Medication alignment matters: taper schedules are conservative, drug–drug interactions checked, and post-session periods protected from sedatives that blunt consolidation. Equity is engineered in—interpreters, low-literacy materials, tele options, and cost navigation—so access isn’t gated by wealth or geography. If you’re comparing models at a psychedelic therapy conference, you’ll find role definitions (therapist, prescriber, sitter, peer), emergency plans, and documentation templates that fit real clinics. Finally, step back from hype to systems thinking: dashboards follow function, sleep, and participation, not just symptom scores, and tie escalation or de-escalation to clear thresholds. For escalation pathways after nonresponse, see Treatment-Resistant Depression; for circuit translation and patient education, pair with Neuroimaging and Circuits. The destination is disciplined innovation: fewer relapses, safer practice, and changes that last outside the therapy room.